Physician profile
Mir Ali Mohammad
NPI 1861728198
$2,379.19
in general payments reported to CMS, 2019-2025
12 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $498 · 2021: $487 · 2022: $551 · 2023: $159 · 2024: $236 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $586.64 | 2019-2025 | Zerbaxa, Capvaxive, Pifeltro |
| Abbvie INC. | $384.26 | 2020-2025 | |
| Gilead Sciences, INC. | $297.33 | 2022-2024 | Veklury |
| Allergan, INC. | $273.39 | 2019-2020 | |
| Viiv Healthcare Company | $270.24 | 2020-2024 | Cabenuva |
| Paratek Pharmaceuticals, INC. | $172.04 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $109.56 | 2019-2022 | |
| Melinta Therapeutics, LLC | $97.31 | 2019-2021 | |
| Janssen Biotech, INC. | $78.62 | 2019-2022 | |
| Shionogi INC | $69.36 | 2021-2022 | |
| Astellas Pharma US INC | $23.61 | 2022 | |
| Insmed, INC. | $16.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.